AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hosp...(ed necessary becausethey had serious med...),Health

Date:9/28/2007

ed necessary because they had serious medical conditions, which included appendicitis. Of these 120 patients, 94% (95% CI =88-98) or 113 had a positive AppyScore. The usefulness of the AppyScore test in patients with abdominal pain may exceed the boundaries of patients with appendicitis because patients with other serious conditions are also identified in the screening process.

About Appendicitis

Annually, in the U.S. alone, an estimated 6,000,000 patients enter hospital emergency rooms complaining of abdominal pain and who could potentially have appendicitis. Upon entering the ER, the current standard of care for these patients is to draw blood samples and take vital signs. Depending upon the determination of the ER physician, a CT scan may also be scheduled. CT scans generally take several hours to schedule and complete the procedure and interpret the results. Moreover, CTs are expensive, costing on average an estimated $1,500 to $3,000 for each scan and subject the patient (generally who are adolescents) to high levels of ionizing radiation. Every year, it is estimated that more than 700,000 patients in the U.S. are diagnosed with appendicitis and have their appendixes surgically removed. An estimated 100,000 or about 14% are later determined to have had a normal appendix. Meanwhile, around 100,000 other patients with real appendicitis are diagnosed incorrectly or not in time and suffer a perforated appendix, a potentially fatal condition requiring emergency surgery which involves greater expense, risk, significantly longer treatment, and extended hospitalization.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic app
'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis